JWJing Wei

Jing Wei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jing Wei has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Allen C Gao

    Department of Urologic Surgery, University of California, Davis, Sacramento, CA, 95817, USA

    1 shared publication
  • Boyang Jason Wu

    Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, USA

    1 shared publication
  • Eva Corey

    Department of Urology, University of Washington, Seattle, WA 98195, USA

    1 shared publication
  • Jing Wang

    Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, 99202, USA.

    1 shared publication
  • Jingjing Li

    Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, 99202, USA

    1 shared publication
  • Tianjie Pu

    Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA 99202, USA

    1 shared publication

Latest Publications

  • Open Access

    PlexinD1 is a driver and a therapeutic target in advanced prostate cancer

    by Jing Wei, Jing Wang, Wen Guan, Jingjing Li, Tianjie Pu, Eva Corey, Tzu-Ping Lin, Allen C Gao, Boyang Jason Wu

    Aggressive prostate cancer (PCa) variants associated with androgen receptor signaling inhibitor (ARSI) resistance and metastasis remain poorly understood. Here, we identify the axon guidance semaphorin receptor PlexinD1 as a crucial driver of cancer aggressiveness in metastatic castration-resistant prostate cancer (CRPC). High PlexinD1 expression in human PCa is correlated with adverse clinical outcomes. PlexinD1 critically maintains CRPC aggressive behaviors in vitro and in vivo, and confers stemness and cellular plasticity to promote multilineage differentiation including a neuroendocrine-like phenotype for ARSI resistance. Mechanistically, PlexinD1 is upregulated upon relief of AR-mediated transcriptional repression of PlexinD1 under ARSI treatment, and subsdquently transactivates ErbB3 and cMet via direct interaction, which triggers the ERK/AKT pathways to induce noncanonical Gli1-dictated Hedgehog signaling, facilitating the growth and plasticity of PCa cells. Blockade of PlexinD1 by the protein inhibitor D1SP restricted CRPC growth in multiple preclinical models. Collectively, these findings characterize PlexinD1’s contribution to PCa progression and offer a potential PlexinD1-targeted therapy for advanced PCa.